Assertio
ASRT

$1.35

3.85%

Market Cap: $129M

About: Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.

Employees: 30

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

2,243% more call options, than puts

Call options by funds: $1.59M | Put options by funds: $68K

31% more capital invested

Capital invested by funds: $42.7M [Q1] → $56.1M (+$13.4M) [Q2]

0.69% more ownership

Funds ownership: 46.9% [Q1] → 47.59% (+0.69%) [Q2]

0% more funds holding

Funds holding: 103 [Q1] → 103 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 26

42% less repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 36

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$3

122%

upside

Avg. target

$3.50

159%

upside

High target

$4

196%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

Maxim Group Naz Rahman 0% 1-year accuracy 0 / 8 met price target	122%upside $3	Buy Initiated	26 Jul 2024
HC Wainwright & Co. Raghuram Selvaraju 42% 1-year accuracy 116 / 274 met price target	196%upside $4	Buy Initiated	3 Jul 2024

See Analyst Rankings

Financial journalist opinion

Assertio Holdings: Management Change Could Improve Comeback Chances

After losing exclusivity with its prior flagship drug, pharma firm Assertio Holdings (ASRT) is angling for a comeback with a new flagship drug product. However, Assertio's latest fiscal results were mixed at best, suggesting challenges ahead with its turnaround efforts. Still, with a new CEO at the helm, there may now be greater potential for ASRT to not only experience improved fiscal performance, but experience a market re-rating as well.

Assertio Holdings: Management Change Could Improve Comeback Chances

Assertio to Participate in the HC Wainwright and Lake Street Conferences in New York City September 10-12, 2024

LAKE FOREST, Ill., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that Ajay Patel, Chief Financial Officer, will host investor meetings at two investor conferences taking place in New York City during September 10-12, 2024.

Assertio to Participate in the HC Wainwright and Lake Street Conferences in New York City September 10-12, 2024

Assertio Holdings, Inc. (ASRT) Q2 2024 Earnings Call Transcript

Assertio Holdings, Inc. (NASDAQ:ASRT ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Matthew Kreps - Darrow Associates, IR Brendan O'Grady - Chief Executive Officer Ajay Patel - Senior Vice President and Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Raghuram Selvaraju - H.C. Wainwright Naz Rahman - Maxim Group Scott Henry - Alliance Global Partners James Sidoti - Sidoti and Company Operator Thank you for standing by.

Assertio Holdings, Inc. (ASRT) Q2 2024 Earnings Call Transcript

Zacks Investment Research

Assertio (ASRT) Reports Q2 Loss, Tops Revenue Estimates

Assertio (ASRT) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.13 per share a year ago.

Assertio (ASRT) Reports Q2 Loss, Tops Revenue Estimates

Assertio Reports Second Quarter 2024 Financial Results

Second Quarter Total Net Product Sales of $30.7 Million Rolvedon Growth Continues, with $15.1 million in Net Product Sales $7.4 Million in Cash Flow from Operations, Cash and Short-Term Investments Increases to $88.4 Million LAKE FOREST, Ill., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today reported financial results for the second quarter ended June 30, 2024.

Assertio Reports Second Quarter 2024 Financial Results

Zacks Investment Research

Earnings Preview: Assertio (ASRT) Q2 Earnings Expected to Decline

Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Assertio (ASRT) Q2 Earnings Expected to Decline

Assertio Holdings, Inc. to Report Second Quarter 2024 Financial Results on August 7, 2024

LAKE FOREST, Ill., July 24, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that it will release second quarter 2024 financial results on Wednesday, August 7, 2024, after the market close. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time.

Assertio Holdings, Inc. to Report Second Quarter 2024 Financial Results on August 7, 2024

Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LAKE FOREST, Ill., July 09, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that effective July 1, 2024, the Compensation Committee of the Company's Board of Directors granted four newly-hired employees a total of 44,575 restricted stock units (“RSUs”) and 142,910 stock options (“options”).

Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ASSERTIO ALERT: Bragar Eagel & Squire, P.C. is Investigating Assertio Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Assertio Holdings, Inc. (NASDAQ: ASRT) on behalf of long-term stockholders following a class action complaint that was filed against Assertio on January 5, 2024 with a Class Period from March 9, 2023 to November 8, 2023. Our investigation concerns whether the board of directors of Assertio have breached their fiduciary duties to the company.

ASSERTIO ALERT: Bragar Eagel & Squire, P.C. is Investigating Assertio Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Assertio: An Extremely Asymmetric Bet Skewed To The Upside

Assertio Holdings, Inc. shares present a significant upside potential due to ongoing turnaround efforts and proven success in monetizing underappreciated pharma assets. The merger with Spectrum Pharmaceuticals saved Assertio from potential collapse after a generic drug approval, providing a new opportunity with Rolvedon. A DCF valuation model suggests a fair equity value of $4.00 per share, indicating a potential 300% upside from the current share price, but high risks are involved.

Assertio: An Extremely Asymmetric Bet Skewed To The Upside

See News Rankings